PRKDC and glioblastoma: Consequently, we asked whether inhibition of DNA-PKcs with M3814 (nedisertib), a DNA-PKcs inhibitor currently in clinical studies44, promotes vulnerability of PPR GBM when used in combination with ionizing radiation (IR), the key element in the standard of care for patients with GBM.